BRPI0413349A - compostos de oxazol para o tratamento de doenças neurodegenerativas - Google Patents

compostos de oxazol para o tratamento de doenças neurodegenerativas

Info

Publication number
BRPI0413349A
BRPI0413349A BRPI0413349-8A BRPI0413349A BRPI0413349A BR PI0413349 A BRPI0413349 A BR PI0413349A BR PI0413349 A BRPI0413349 A BR PI0413349A BR PI0413349 A BRPI0413349 A BR PI0413349A
Authority
BR
Brazil
Prior art keywords
neurodegenerative diseases
treatment
compounds
oxazole compounds
formula
Prior art date
Application number
BRPI0413349-8A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413349A publication Critical patent/BRPI0413349A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE OXAZOL PARA O TRATAMENTO DE DOENçAS NEURODEGENERATIVAS". A presente invenção se refere a compostos da Fórmula em que R¬ 3¬, R¬ 5¬, R¬ 6¬, R¬ 7¬ e Z e outras variáveis enumeradas na forma de um ou mais de R¬ 3¬, R¬ 5¬, R¬ 6¬, R¬ 7¬ e Z, são como definidos. Os compostos da Fórmula I possuem atividade na inibição da produção de peptida A<225>. Esta invenção também se refere a composições farmacêuticas e métodos para tratar doenças, por exemplo, doenças neurodegenerativas, por exemplo, doença de Alzheimer, em um mamífero, que compreende compostos da Fórmula I.
BRPI0413349-8A 2003-08-06 2004-08-04 compostos de oxazol para o tratamento de doenças neurodegenerativas BRPI0413349A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49288403P 2003-08-06 2003-08-06
US49802803P 2003-08-27 2003-08-27
PCT/US2004/025023 WO2005016267A2 (en) 2003-08-06 2004-08-04 Oxazole compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0413349A true BRPI0413349A (pt) 2006-10-10

Family

ID=34197958

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413349-8A BRPI0413349A (pt) 2003-08-06 2004-08-04 compostos de oxazol para o tratamento de doenças neurodegenerativas

Country Status (13)

Country Link
US (1) US7112599B2 (pt)
EP (1) EP1653952A4 (pt)
JP (1) JP2007501244A (pt)
AR (1) AR046327A1 (pt)
BR (1) BRPI0413349A (pt)
CA (1) CA2534529A1 (pt)
MX (1) MXPA06001480A (pt)
PA (1) PA8608601A1 (pt)
PE (1) PE20050337A1 (pt)
SV (1) SV2005001840A (pt)
TW (1) TW200510351A (pt)
UY (1) UY28458A1 (pt)
WO (1) WO2005016267A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1730119T3 (da) * 2004-03-23 2008-08-11 Pfizer Prod Inc Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
AU2006293619A1 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
SG11201407919WA (en) * 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
WO2019183587A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN113651805B (zh) * 2021-07-19 2023-07-25 安徽医科大学 一种1,2,4-噁二唑-吡啶类化合物及其在治疗阿尔茨海默症中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3094462A (en) * 1961-09-18 1963-06-18 Mcneilab Inc Therapeutic reaction complex for muscle relaxation
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
GB1264258A (pt) * 1970-10-10 1972-02-16
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6169102B1 (en) * 1996-06-25 2001-01-02 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-Helicobacter pylori agent
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
MXPA05003432A (es) * 2002-10-09 2005-07-05 Pfizer Prod Inc Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos.
JP2006504796A (ja) * 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性性障害を処置するためのチアゾール化合物
JP4286788B2 (ja) * 2002-12-23 2009-07-01 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ１エンハンサーとしてのオキサゾール
MXPA05007388A (es) * 2003-01-13 2005-09-12 Hoffmann La Roche Derivados de benzoxazol y su uso como ligandos de receptor de adenosina.

Also Published As

Publication number Publication date
US7112599B2 (en) 2006-09-26
EP1653952A4 (en) 2007-04-04
TW200510351A (en) 2005-03-16
UY28458A1 (es) 2005-03-31
MXPA06001480A (es) 2006-05-15
WO2005016267A2 (en) 2005-02-24
US20050032859A1 (en) 2005-02-10
SV2005001840A (es) 2005-11-04
JP2007501244A (ja) 2007-01-25
PE20050337A1 (es) 2005-06-06
CA2534529A1 (en) 2005-02-24
AR046327A1 (es) 2005-12-07
EP1653952A2 (en) 2006-05-10
PA8608601A1 (es) 2005-03-03
WO2005016267A3 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos
BRPI0409721A (pt) compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
BRPI0416283A (pt) compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BRPI0410238A (pt) compostos orgánicos
BRPI0413349A (pt) compostos de oxazol para o tratamento de doenças neurodegenerativas
BR0313946A (pt) Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
BRPI0518907A2 (pt) compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de h3 e sua utilizaÇço
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
UY29161A1 (es) Nuevos heterociclos
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
BRPI0416284A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e sua utilização
BRPI0615614A2 (pt) compostos orgánicos
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
BR0211121A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/421; C07D 263/04, 263/16, 263/34, 413/00; A61P 25/00

Ipc: A61K 31/421 (2011.01), C07D 263/04 (2011.01), C07D

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.